Associate Professor Chris McCormack is the head dermatologist at the Peter Macallum Cancer Centre. He is actively involved in clinical and academic work at the centre. He is specialised in skin cancer diagnosis and management including Melanoma and Non-melanoma Skin Cancers. Dr McCormack also runs a cutaneous lymphoma clinic, which is a multidisciplinary clinic and one of the largest of its kind in the world.
Hughes CF, Khot A, McCormack C, Lade S, Westerman DA, Twigger R, Buelens O, Newland K, Tam C, Dickinson M, Ryan G, Ritchie D, Wood C, Prince HM, Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. Blood, 2015. 125(1): p. 71-81.
Lacouture, M.E., et al., Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist, 2013. 18(3): p. 314-22.
Shen, S., et al., The use of methotrexate in dermatology: a review. Australas J Dermatol, 2012. 53(1): p. 1-18.
McCormack, C.J., et al., Atypical Spitzoid neoplasms: a review of potential markers of biological behavior including sentinel node biopsy. Melanoma Res, 2014. 24(5): p. 437-47.
Ellis, L., et al., Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res, 2008. 14(14): p. 4500-10.
Arulogun, S.O., et al., Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood, 2008. 112(8): p. 3082-7.
McCormack, C.J., J.W. Kelly, and A.P. Dorevitch, Differences in age and body site distribution of the histological subtypes of basal cell carcinoma. A possible indicator of differing causes. Arch Dermatol, 1997. 133(5): p. 593-6.